News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
6,143 Results
Type
Article (595)
Press Release (5548)
Section
Business (1304)
Career Advice (6)
Deals (227)
Drug Delivery (1)
Drug Development (543)
Employer Resources (1)
FDA (556)
Job Trends (104)
News (2527)
Policy (226)
Tag
Academia (31)
Accelerated approval (1)
Alliances (259)
Alzheimer's disease (12)
Approvals (563)
Artificial intelligence (8)
Bankruptcy (2)
Best Places to Work (83)
Brain cancer (2)
Breast cancer (6)
Cancer (14)
Cardiovascular disease (22)
Career advice (6)
CAR-T (1)
CDMO (1)
Cell therapy (1)
Clinical research (535)
Collaboration (5)
Company closure (1)
Compensation (7)
Complete response letters (2)
COVID-19 (9)
C-suite (12)
Data (114)
Depression (2)
Diabetes (2)
Diagnostics (25)
Digital health (1)
Duchenne muscular dystrophy (3)
Earnings (459)
Employer resources (1)
Events (708)
Executive appointments (7)
FDA (623)
Funding (15)
Gene therapy (10)
GLP-1 (5)
Government (34)
Guidances (7)
Healthcare (101)
Hematology (1)
Huntington's disease (3)
Immunology and inflammation (3)
Indications (2)
Infectious disease (11)
Inflammatory bowel disease (1)
Intellectual property (3)
Interviews (4)
IPO (61)
Job creations (23)
Job search strategy (3)
Labor market (1)
Layoffs (1)
Legal (30)
Liver cancer (1)
Longevity (1)
Lung cancer (1)
Lymphoma (1)
Management (1)
Manufacturing (4)
Marketing (1)
Medical device (290)
Medtech (293)
Mergers & acquisitions (187)
Metabolic disorders (35)
Multiple sclerosis (2)
Neuropsychiatric disorders (4)
Neuroscience (55)
NextGen: Class of 2026 (43)
Non-profit (22)
Obesity (31)
Opinion (1)
Parkinson's disease (6)
Patents (9)
Patient recruitment (8)
People (413)
Phase 1 (96)
Phase 2 (213)
Phase 3 (227)
Pipeline (160)
Policy (2)
Postmarket research (53)
Preclinical (40)
Psychedelics (1)
Rare diseases (15)
Real estate (24)
Regulatory (252)
Research institute (20)
RNA editing (1)
Schizophrenia (19)
Series A (1)
Series B (3)
Special edition (1)
Sponsored (1)
Startups (21)
Supply chain (1)
The Weekly (3)
Vaccines (5)
Venture capital (2)
Weight loss (6)
Women's health (1)
Date
Last 7 days (10)
Last 30 days (25)
Last 365 days (271)
2026 (198)
2025 (264)
2024 (291)
2023 (299)
2022 (375)
2021 (394)
2020 (332)
2019 (377)
2018 (286)
2017 (312)
2016 (319)
2015 (374)
2014 (282)
2013 (249)
2012 (265)
2011 (289)
2010 (275)
Location
Africa (1)
Arizona (5)
Asia (142)
Australia (17)
California (121)
Canada (64)
China (4)
Colorado (11)
Connecticut (33)
Delaware (6)
Europe (824)
Florida (6)
Georgia (3)
Illinois (31)
Japan (4)
Kansas (1)
Louisiana (1)
Maine (5)
Maryland (10)
Massachusetts (127)
Michigan (1)
Minnesota (4)
Missouri (4)
Nevada (5)
New Hampshire (1)
New Jersey (23)
New York (14)
North Carolina (55)
Northern California (50)
Ohio (2)
Pennsylvania (33)
South America (7)
South Carolina (14)
Southern California (61)
Tennessee (3)
Texas (8)
United States (521)
Utah (3)
Washington State (2)
6,143 Results for "rhythm".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease
Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.
June 15, 2026
·
2 min read
·
Tristan Manalac
Obesity
Rhythm’s Imcivree Fails Late-Stage Weight Loss Trial in Rare Obesities
The Phase 3 EMANATE study is a basket trial looking at the efficacy of Rhythm Pharmaceuticals’ injectable obesity drug across four types of obesities driven by specific genetic mutations.
March 17, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
August 17, 2026
·
9 min read
Press Releases
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - August 4, 2026
August 4, 2026
·
8 min read
Press Releases
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
August 4, 2026
·
23 min read
Press Releases
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
August 24, 2026
·
10 min read
Press Releases
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
July 21, 2026
·
8 min read
Press Releases
Rhythm Pharmaceuticals Announces Participation in Upcoming June 2026 Investor Conferences
May 26, 2026
·
7 min read
Press Releases
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
August 4, 2026
·
11 min read
Press Releases
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
May 29, 2026
·
10 min read
1 of 615
Next
